Tripos Inc. - 500 Beiträge pro Seite

[Teerwerk]

Wer kennt diese hochspekulative Aktie genauer???
Neue Forschungsergebnisse??
Aktie angeblich nur für Trader geeignet (vgl. Taipan-Börsenbrief)???
Warum?

[Teerwerk]

Kurs steigt in den letzten Tagen. Wer kennt die neuen Fakten??

[Teerwerk]

Interessanter Wert einer Zulieferfirma der Pharma- und Biotechbranche mit einem aussichtsreichem Standbein in der Nanotechbranche.

[brf1]

kam heute als Email

.....
Marco Beckmann, Fondsberater des H&A Lux DAC NANOTECH-FONDS (WKN 813843), spricht in einem brandneuen Audio-Interview über neue Trends und Branchen und stellt zwei potenzielle Nano-Highflyer vor:
http://news.boersenmedien.de/re?l=nx5g4X1m1lshX2
.....

Die beiden "Nano-Highflyer" sind Tripos und Spire.

weitere Kernaussage: " ... die bekannten Nanoaktien sind überbewertet..., jetzt ist die 2. Reihe dran...

Interessantes Interview, hört es Euch selber an.


gruss brf

[Teerwerk]

Wäre auch sinnvoll wenn Werte wie Tripos aus der zweiten Reihe endlich ihre Chance bekommen würden.

[Michael@]

Moin moin Teerwerk,

habe Tripos auch im Depot... und ich denke das wird ein Knaller werden...

Der Aktionär empfiehlt in der Ausgabe vom 07.04.2004 diesen Wert auf der Seite 24. Genaueres kann ich Dir
morgen SChreiben da ich unterwegs bin... oder Du kaufst Ihn Dir selbst...

Das ist kein Zocker Wert... Die Schreiben seit 2002 schwarze Zahlen und und in 2003 einen Gewinn von 2,3 Mio USD.... Die Umsatz und Gewinn Prognosse wurde für 1 Quart.
2004 um ca. 10 15 % weiß es jetzt nicht genau angehoben...

Denke mal das einige jetzt auch durch den Aktionär aufmeksam werden...

Gruß... und bis bald mitch

[IImaximusII]

Hab mir heute auch tripos in mein depot gelegt

Tripos steigert angeblich seine Umsätze seit fünf Jahren konstant. Seit drei jahren fällt auch der Gewinn je Aktie auf Gesamtjahresbasis wieder positiv aus.

Noch fristet das Unternehmen ein Schattendasein. Mit einer aktuellen Marktkapitalisierung von 50,4 Millionen Doller ist die Aktie von Tripos noch billig zu haben

[KOC II]

Hallo

Tripos Inc. Quick Quote: TRPS 5.62 (Even)




Tripos Reports Fourth-Quarter and Full-Year 2003 Financial Results
3/31/04

ST. LOUIS, Mar 31, 2004 /PRNewswire-FirstCall via COMTEX/ --
Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced financial results for the fourth quarter and full year ended Dec. 31, 2003. The company also announced restated financial results for prior years as a result of a revised revenue recognition policy with respect to certain software licenses. Except as otherwise noted, all financial comparisons are based on restated amounts.

`Our achievement of 10 percent revenue growth in 2003 was significant, particularly in light of difficult market conditions,`said Dr. John P. McAlister, president and CEO of Tripos. `During the year we made noteworthy progress in the successful delivery of contracted business, as well as diversifying our customer base through the addition of several new biotechnology customer relationships. We recently completed the expansion of our discovery research facilities in the United Kingdom, positioning ourselves for increased Discovery Research business in 2004 and beyond.`

For 2003, including the three months ended Dec. 31, 2003: -- For 2003, Tripos posted revenues of $54.1 million, a 10 percent increase from the previous year`s revenues of $49.1 million. - Revenues for the fourth quarter of 2003 were $12.6 million compared with $14.7 million in the fourth quarter of 2002. -- Pretax income was $3.7 million for the year, compared with pretax loss of $0.6 million for the same period in 2002. - Pretax loss for the fourth quarter was $0.8 million, compared with pretax income of $0.3 million in the previous year. -- Net income for 2003 was $2.1 million, or $0.23 per diluted share after including the valuation allowance for deferred tax assets. This is compared with a net loss of $0, or $0.00 per diluted share, for full- year 2002. - Net loss for the fourth quarter of 2003 was $0.5 million, or $0.05 per basic share, compared with net loss of $0 million, or $0.00 per basic share, in the fourth quarter of 2002. -- Excluding gains from sales of common stock of Arena Pharmaceuticals Inc., 2003 net loss was $1.7 million, or $0.19 per basic share, compared with a net loss for 2002 of $2.2 million, or $0.26 per basic share. - Excluding gains from sales of common stock of Arena Pharmaceuticals, fourth-quarter 2003 net loss was $0.8 million, or $0.09 per basic share, compared with a fourth-quarter 2002 net loss of $0.7 million, or $0.08 per basic share.
`Our revenue growth in 2003 came primarily from our Discovery Research products and services, which increased more than 45 percent this year,` McAlister said. `Discovery Software products and support performed well, increasing 7 percent compared with 2002. Our Discovery Informatics services did not achieve our objectives for the year, and we have taken several steps, including reorganizing our sales and marketing strategy, to improve this performance. We reported strong cost containment in our sales and marketing and general and administrative expenses in 2003, decreasing both compared with 2002. Additionally, during the past two years we have been able to use gains from sales of our successful investment in Arena Pharmaceuticals to help fund the construction of our expanded Discovery Research laboratory.`

2004 Outlook

`We believe the investments we have made these past two years in our Discovery Informatics and Discovery Research business areas will drive continued revenue growth in our highly competitive market in 2004,`McAlister said. `Operationally we are focused on delivering a return to operating profitability for our shareholders.`

Webcast Information

Tripos will host a conference call and webcast today at 5 p.m. EST to discuss these financial results in detail. Those who want to participate in the webcast should visit the Tripos Web site at http://www.tripos.com/ . The Tripos webcast archive will be available beginning at 7 p.m. EST today, and will remain on the Tripos Web site through April 30, 2004.

About Tripos, Inc.

Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos`Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos`Discovery Research (DR) business, Tripos`medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com/ .

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as `expects,``anticipates,` `projects,``estimates,``intends,``plans,``believes,`variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

Tripos, Inc. Condensed Results of Operations (in thousands, except per-share data) Unaudited Audited Three Months Ended Twelve Months Ended Dec. 31, Dec. 31, Dec. 31, Dec. 31, 2003 2002 2003 2002 Restated Restated Net sales Discovery Software products and support $6,092 $5,718 $23,702 $22,182 Discovery Informatics services 207 3,204 3,241 7,956 Discovery Research products and services 6,140 5,514 26,245 18,016 Hardware 178 246 960 937 Total net sales 12,617 14,682 54,148 49,091 Cost of sales 7,472 7,126 26,240 20,601 Gross margin 5,145 7,556 27,908 28,490 Operating expenses Sales and marketing 3,294 3,796 13,195 15,476 Research and development 2,716 2,573 12,917 10,102 General and administrative 1,596 1,962 7,241 6,886 Total operating expenses 7,606 8,331 33,353 32,464 Income (loss) from operations (2,461) (775) (5,445) (3,974) Other income, net 1,670 1,088 9,114 3,419 Income (loss) before income taxes (791) 313 3,669 (555) Income tax expense (benefit) (339) 331 1,569 (587) Net income (loss) (452) (18) 2,100 32 Preferred stock dividend - - - 37 Net income (loss) allocable to common shareholders (452) (18) $2,100 $(5) Basic income (loss) per share $(0.05) $(0.00) $0.23 $(0.00) Diluted income (loss) per share $(0.05) $(0.00) $0.23 $(0.00) Basic weighted average shares 8,992 8,802 8,949 8,615 Diluted shares outstanding 8,992 8,802 9,333 8,615 Tripos, Inc. Consolidated Balance Sheets (in thousands, except per-share data) Audited Dec. 31, Dec. 31, 2003 2002 Assets: Restated Current assets: Cash and cash equivalents $2,945 $1,861 Marketable securities 1,121 8,440 Accounts receivable 16,662 15,849 Note receivable from former executive -- 137 Inventory 12,863 7,375 Prepaid expenses 5,054 4,228 Total current assets 38,645 37,890 Property and equipment, less accumulated depreciation 27,926 20,373 Capitalized development costs 2,417 1,402 Goodwill, net of amortization 965 965 Investments recorded at cost 1,352 1,200 Deferred income taxes -- 476 Other, net 390 665 Total assets $71,695 $62,971 Liabilities and shareholders`equity: Current liabilities: Current portion of long-term debt and capital leases $10,510 $455 Accounts payable 2,405 1,128 Accrued expenses 7,688 6,562 Deferred revenue 17,079 15,693 Deferred income taxes 219 1,427 Total current liabilities 37,901 25,265 Long-term portion of capital leases 2,463 149 Long-term debt 3,915 7,233 Deferred income taxes 422 -- Shareholders`equity Common stock 45 44 Additional paid-in capital 36,502 36,077 Retained earnings (deficit) (8,321) (10,421) Other comprehensive income (deficit) (1,232) 4,624 Total shareholders`equity 26,994 30,324 Total liabilities and shareholders`equity $71,695 $62,971
SOURCE Tripos, Inc.

vielleicht hilft es einigen !!!!!!!!!!!!


Gruss

KOC II

[Teerwerk]

Tripos wieder über 5 Euro. Hohe Aktienumsätze. Geht es mit diesem Unternehmen nun endlich aufwärts? Wer hat nähere Infos?

[Kautzie]

Hallo!
Die Aktie ist sicherlich interessant. Denke das auch Charttechnisch bald einiges drin sein wird. Aber bedenkt auch das Risikio. Sicherlich wird im Aktionär die Chancen und Aussichten gut erläutert, aber was ist wenn eine andere Firma eine genauso gute oder sogar bessere und billigere Sofwarelösung auf dem Markt bringt. Womit würde dann Tripos sein Geld verdienen.
(Dies sollte nur als kleiner Hinweis dienen.)

[Michael@]

HI Kautzie,

scheinst ein alter metabox veteran zu sein... das waren noch zeiten... naja... vieleicht nicht die besten...

Freue mich aber das Du dein Wissen benutzt um evtl Risiken und Lücken aufzuzeigen... das gehört eben dazu

Gruß... und viele grüne Zahlen

[KOC II]

Hallo

Der nanotech-report hat 2500 Stück für 4,95
ins depot gelegt!

Gruss
KOC II

[Kautzie]

Hallo!
Dies habe ich bei Tripos unter Nachrichten bei wallstreetonline entdeckt. Leider ist mein Englisch Katastrophal.
Vielleicht kann ja jemand den Inhalt ein wennig zusammen fassen.

Thursday, 15. April 2004 | 14:06 Uhr
Tripos Selects Three Recipients of Technology Award; International Competition Rewards High-Potential Research With Access to Compounds and Software for Rapid Drug Discovery
Tripos Selects Three Recipients of Technology Award; International Competition Rewards High-Potential Research With Access to Compounds and Software for Rapid Drug Discovery



BW5206 APR 15,2004 5:06 PACIFIC 08:06 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos Selects Three Recipients of TechnologyAward; International Competition Rewards High-Potential Research WithAccess to Compounds and Software for Rapid Drug Discovery

Health/Medical Writers/High-Tech Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--April 15, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, has announced the North Americanand European recipients of its Hits-to-Leads Awards Program. The threeselected organizations and their areas of focus are these:



--
Apath LLC, Missouri -- broad-spectrum antiviral drug therapies

--
Cancer Research UK -- oncology therapies

--
EntreMed Inc., Maryland -- oncology therapies

Tripos´ Hits-to-Leads program grants proprietary products andservices to overcome challenges faced by many researchers -- lack ofaccess to a wide array of compounds and the software to efficientlyscan and track potential leads -- without a major investment ininfrastructure. "Our goal is to accelerate drug discovery withorganizations that have proved their potential to find importantmedicines to improve the quality of human life," said Dr. Peter Hecht,Ph.D., senior vice president of discovery research operations atTripos.
Each recipient will receive diverse compounds, proprietaryscreening software and customized data analysis through the followingproducts:

-- LeadScreen(TM), 50,000 high-quality drug-like screening
compounds

-- SARNavigator(TM) , a desktop data-analysis technology

-- Customized data analysis developed by Tripos´ scientists
working closely with the winners

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

--30--SP/se* CONTACT: Tripos, Inc. Edward E. Hodgkin, 314-647-8837 OR Common Ground Public Relations Inc. for Tripos Denise Bentele Heintz, 636-530-3603 KEYWORD: MISSOURI INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

-------------------------------------------------------

Den Anfang habe ich mal in ein Übersetzungsprogramm kopiert.

"Tripos wählt drei Empfänger Technologie-Preis vor; Weltweite
Konkurrenz belohnt Hoch-Potential Forschung mit Zugang zu den Mitteln
und Software für schnelle Droge-Entdeckung"

----------------------------------------------------------

[KOC II]

Tripos Announces Webcast of 2004 First Quarter Financial Results
via COMTEX

April 27, 2004

ST. LOUIS, Apr 27, 2004 (BUSINESS WIRE) --

Tripos, Inc. (Nasdaq: TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced it will conduct a live audio webcast presentation and conference call to discuss quarterly financial results for the period ended March 31, 2004, at 10 a.m. EST on Thursday, April 29th.

John P. McAlister, Ph.D., president and chief executive officer of Tripos, Jim Rubin, senior vice president and chief financial officer of Tripos, Dieter Schmidt-Base, senior vice president of worldwide sales, and John Yingling, vice president and chief accounting officer of Tripos, will host the conference call. Tripos will announce its financial results for the first quarter in a press release to be issued at 7 a.m. EST the same day. The press release and live webcast will be accessible through the Tripos Web site at http://www.tripos.com/. The webcast will be archived on the site starting at 1 p.m. EST on April 29th and will be available there until May 29, 2004.

About Tripos, Inc.

Tripos (Nasdaq: TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos`Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos` Discovery Research (DR) business, Tripos`medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com/.

This press release may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as `expects,``anticipates,``projects,``estimates,``intends,``plans,` `believes,`variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. We have identified certain factors that could cause actual results to differ materially from the forward-looking statements in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K. Except as otherwise required under federal securities laws and the rules and regulations of the SEC, we do not have any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, changes in assumptions or otherwise.

SOURCE: Tripos, Inc.

Tripos, Inc. Jim Rubin, 314-647-8837, ext. 3137 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail]

Customize your Business Wire news &multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com.

Copyright (C) 2004 Business Wire. All rights reserved.



Gruss
KOC II

[Kautzie]

Tripos Reports First Quarter 2004 Financial Results; Company Achieves Strong Revenue Growth of 13 Percent
Tripos Reports First Quarter 2004 Financial Results; Company Achieves Strong Revenue Growth of 13 Percent



BW5163 APR 29,2004 3:03 PACIFIC 06:03 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos Reports First Quarter 2004 FinancialResults; Company Achieves Strong Revenue Growth of 13 Percent

Business Editors/Health/Medical Writers

ST. LOUIS--(BUSINESS WIRE)--April 29, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced financial resultsfor the first quarter of 2004.

The company announced the following results for the three monthsending March 31, 2004:



--
Tripos posted revenues of $15.5 million, a 13 percent increase from the previous year´s first quarter revenues of $13.7 million.

--
Operating loss in the first quarter of 2004 was $82,000, compared with an operating loss of $290,000 in the first quarter of 2003.

--
Pretax loss was $40,000 for the first quarter, compared with pretax income of $647,000 for the same period in 2003.

--
Net loss for the first quarter of 2004 was $25,000, or $0.00 per basic share. This is compared with net income of $370,000, or $0.04 per diluted share, for the first quarter of 2003.

--
Excluding gains from sales of common stock of Arena Pharmaceuticals Inc., net loss was$113,000, or $0.01 per basic share, compared with a net loss of $376,000, or $0.04 per basic share, for the same quarter in 2003.

"Our revenue growth this quarter represents successful expansionof our Discovery Research business and the continued strength of ourDiscovery Informatics products business," said Dr. John P. McAlister,president and CEO of Tripos. "Discovery Research grew 43 percentcompared with the first quarter of 2003 as a result of our solidprogress with Pfizer and new business initiatives with severalbiotechnology companies. Orders remain strong in our DiscoveryInformatics products business, providing continued revenue stabilityin future periods as these revenues are recognized over the life ofthe contract.
"Despite strong performance on the revenue line and efficientexpense management, our operating profits were adversely impacted bycurrency exchange rates, costs to move into our new researchlaboratories, and various one-time costs such as those associated withthe restatement. Overall, these results demonstrate progress towardour key 2004 objectives of achieving continued top-line revenue growthand operating profitability for the year," McAlister said.

First Quarter Operational Highlights

Tripos made substantial progress during the quarter on thefollowing strategic initiatives:

-- Tripos amended its multiyear Pfizer file enrichment contract,
now representing up to $90 million in revenues over its
four-year term, as the companies moved into the next stage of
the collaboration: hit follow-up and large library production.
Successful process development and refinement during the first
two years of this project, as well as reduced dependency on
outsourcing now that the Tripos Discovery Research Center has
been completed, are enabling Tripos to deliver 50 percent more
product to Pfizer in 2004 with only a small increase in staff
over the same period.

-- Schering accepted Tripos´ AUSPYX(TM) data cartridge for Oracle
as the foundation of its Enterprise Chemical Information
Management System (ECIMS). ECIMS is based on Tripos´
proprietary ChemCore(TM) technologies and the Tripos
Electronic Notebook(TM). The companies are planning to deploy
ECIMS globally in 2004.

-- Tripos reorganized its sales and marketing organization to
reach the broadest base of the market with its products and
services and ensure the company has the infrastructure to
support increasing sales activities.

-- The company initiated a three-year collaboration to discover
and optimize small-molecule therapeutics for cardiovascular
disorders with Chronogen Inc., a drug discovery company
developing therapeutics to treat highly prevalent
age-dependent diseases. Under the agreement, Tripos will
provide complete drug discovery chemistry services to
Chronogen.

Change in Independent Auditor

Tripos also announced that Ernst & Young has resigned as itsindependent auditors effective following completion of the firstquarter 2004 review. There are no disagreements between the companyand Ernst & Young on any matter of accounting principles or practices,financial statement disclosure, or auditing scope or procedure. Triposexpects to file a Form 8-K announcing the resignation with theSecurities and Exchange Commission. Under the direction of the AuditCommittee of the Board of Directors, Tripos has begun a search for areplacement auditor that can best meet the needs of the company.
Ernst & Young audited the company´s financial statements that wereincluded in the Form 10-K for the year ended Dec. 31, 2003, and willreview the financial statements included in the Form 10-Q for thequarter ended March 31, 2004.

Webcast Information

Tripos will host a conference call and webcast today at 10 a.m.EDT to discuss these financial results in detail. Those who want toparticipate in the webcast should visit the Tripos Web site athttp://www.tripos.com/. An archived copy of the Tripos webcast will beavailable beginning at 1 p.m. EDT today, and will remain on the TriposWeb site through May 29, 2004.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

Tripos, Inc. Condensed Results of Operations (in thousands, except per-share data) Three Months Ended March 31, March 31, 2004 2003Net sales Discovery software products and support $5,974 $6,083 Discovery Informatics services 715 1,427 Discovery Research products and services 8,727 6,085 Hardware 44 91 --------------------------Total net sales 15,460 13,686 Cost of sales 7,693 5,732 --------------------------Gross margin 7,767 7,954Operating expenses Sales and marketing 3,142 3,223 Research and development 2,828 2,985 General and administrative 1,879 2,036 -------------------------- Total operating expenses 7,849 8,244Loss from operations (82) (290)Other income, net 42 937 --------------------------Income (loss) before income taxes (40) 647Income tax expense (benefit) (15) 277 --------------------------Net income (loss) $(25) $370 ==========================Basic income per share $(0.00) $0.04Diluted income per share $(0.00) $0.04Basic weighted average shares 9,047 8,889Diluted shares outstanding 9,047 9,241 Tripos, Inc. Consolidated Balance Sheets (in thousands, except per-share data) March 31, Dec. 31, 2004 2003 Unaudited -------------------------Assets:Current assets: Cash and cash equivalents $6,526 $2,945 Marketable securities 168 1,121 Accounts receivable 11,743 16,662 Inventory 13,205 12,863 Deferred income taxes -- -- Prepaid expenses 3,714 5,054 ------------------------- Total current assets 35,356 38,645Property and equipment, less accumulated depreciation 29,540 27,926Capitalized development costs, net 2,406 2,417Goodwill 965 965Investments recorded at cost 1,540 1,352Deferred income taxes -- --Other, net 321 390 ------------------------- Total assets $70,128 $71,695 =========================Liabilities and shareholders´ equity:Current liabilities: Current portion of long-term debt and capital leases $6,826 $10,510 Accounts payable 1,854 2,405 Accrued expenses 5,677 7,688 Deferred revenue 22,239 17,079 Deferred income taxes 166 219 ------------------------- Total current liabilities 36,762 37,901Long-term portion of capital leases 2,213 2,463Long-term debt 3,861 3,915Deferred income taxes 68 422Shareholders´ equity Common stock 45 45 Additional paid-in capital 36,520 36,502 Retained earnings (deficit) (8,347) (8,321) Other comprehensive income (deficit) (994) (1,232) ------------------------- Total shareholders´ equity 27,224 26,994 ------------------------- Total liabilities and shareholders´ equity $70,128 $71,695 =========================

--30--SP/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837, ext. 3137 OR Waggener Edstrom Bioscience (Media only) Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY EARNINGS SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[Teerwerk]

Warum sinkt der Kurs wieder einmal? Wer kennt sich bei dieser Aktie genauer aus? Gibt es News?

[Kautzie]

Hallo!
Stöber im Internet mal herum um mal ein paar Informationen über den Wert Tripos ausfindig zu machen.



------------------------------------------------------------


Marco Beckmann: Hier möchte ich Ihnen mit der amerikanischen Tripos Inc und der Spire Corp zwei Werte ans Herz legen, über die Sie im deutschsprachigen Raum wohl noch nichts gehört oder gelesen haben.

Tripos kommt aus dem Bereich Nanotech-Software. Mit der Tripos-Software können Atome und Moleküle am Computer wie auf einem Reißbrett zusammengesetzt und deren Verhalten auf dem Bildschirm simuliert werden. Kunden des Unternehmens sind beispielsweise Pharmakonzerne wie Pfizer. Tripos ist bereits profitabel und wird - und das ist wirklich interessant - vom Großteil der Anleger überhaupt nicht der Nanotechnologie zugeordnet.

Die amerikanische Spire Corp. ist in drei spannenden Gebieten tätig, nämlich im Bereich der Solarzellen, der Biotechnologie und dem Halbleitersektor. Spire ist ein sehr kleines Unternehmen, ist aber ebenfalls schon profitabel, hat also im vergangenen Jahr einen Gewinn erzielt. Gleichzeitig ist die Marktkapitalisierung mit gegenwärtig knapp über 30 Millionen Dollar noch relativ gering.

Beide Unternehmen sind - wie bereits gesagt - noch relativ unbekannt und bieten dem Anleger somit überdurchschnittliches Potenzial!

----------------------------------------------------
http://www.freenet.de/freenet/finanzen/boerse/fonds/nanotech…

[Kautzie]

http://www.freenet.de/freenet/finanzen/boerse/kursliste/anal…

[Kautzie]

http://www.freenet.de/freenet/finanzen/boerse/kursliste/inde…

[Kautzie]

http://www.boersenwelt.de/xist4c/web/displayPortfolioDetails…

[Kautzie]

http://www.myresearch.de/board.php?partner_id=&cmd=show&comp…

[Kautzie]

http://www.freenet.de/freenet/finanzen/boerse/radio/index.ht…




Hier gibt es noch ein Interview zum anschauen. Von Mai 2004

[Kautzie]

Tripos President and CEO to Present at Needham & Company Third Annual Biotechnology Conference
Tripos President and CEO to Present at Needham & Company Third Annual Biotechnology Conference

BW5314 JUN 14,2004 4:03 PACIFIC 07:03 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos President and CEO to Present at Needham& Company Third Annual Biotechnology Conference

Business Editors/Health/Medical Writers
BIOWIRE2K
Needham & Company Inc. Third Annual Biotechnology Conference

ST. LOUIS--(BUSINESS WIRE)--June 14, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery informaticsproducts and chemistry research, today announced that President andChief Executive Officer Dr. John P. McAlister will present at theNeedham & Company Inc. Third Annual Biotechnology Conference onThursday, June 17, 2004, at 2 p.m. EDT. The presentation will takeplace at The New York Palace Hotel in New York.

Who: Dr. John P. McAlister, president and CEO of Tripos

What: Needham & Company Inc. Third Annual Biotechnology Conference

Where: The New York Palace Hotel in New York

When: Thursday, June 17, 2004, at 2 p.m. EDT

In addition, you can access the company´s audio webcast athttp://www.wsw.com/webcast/needham8/trps/.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY TRADESHOW SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 13:03 14.06.04

[Kautzie]

Tripos Appoints BDO Seidman as Independent Auditor
Tripos Appoints BDO Seidman as Independent Auditor



BW5277 JUL 19,2004 3:02 PACIFIC 06:02 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos Appoints BDO Seidman as IndependentAuditor

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--July 19, 2004--Tripos, Inc.(Nasdaq:TRPS) today announced it has appointed BDO Seidman, LLP, asits independent auditor. The appointment is the result of a searchdirected by the Audit Committee of the board of directors of Tripos,following the resignation of Ernst & Young in May of 2004. BDO Seidmanis an international firm that provides auditing services to a widerange of publicly traded companies, and it will review Tripos´financial statements beginning with the quarter ending June 30, 2004.
"The board believes the decision to appoint BDO Seidman is in thebest interest of the company and its stockholders," said Dr. John P.McAlister, president and CEO of Tripos.
BDO Seidman replaces Ernst & Young, which had been Tripos´ auditorsince Tripos became a publicly traded entity in 1994. The decision tochange auditors was not caused by any disagreement between Tripos andErnst & Young on any matter of accounting principles or practices,financial statement disclosure, or auditing scope or procedure.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior,chemistry-research products and services for the biotechnology,pharmaceutical and other life science industries. Tripos collaborateswith clients to accelerate and improve the creation of life-enhancingproducts. Within Tripos´ Discovery Informatics (DI) business, thecompany provides software products and consulting services to develop,manage, analyze and share critical drug discovery information. WithinTripos´ Discovery Research (DR) business, Tripos´ medicinal chemistsand research scientists partner directly with clients in theirresearch initiatives, leveraging state-of-the-art informationtechnologies and research facilities. Headquartered in St. Louis, Mo.,Tripos spans the world with global research operations and aninternational client base. Further information on Tripos can be foundat http://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Tara Gajadhar, 425-638-7000, ext. 5073 (Media only) [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 12:02 19.07.04

[Kautzie]

EMBL-DKFZ Joint Chemical Genomics Facility Selects Tripos As Chemistry Partner in Quest for New Drug Discoveries
EMBL-DKFZ Joint Chemical Genomics Facility Selects Tripos As Chemistry Partner in Quest for New Drug Discoveries



BW5264 JUL 20,2004 3:04 PACIFIC 06:04 EASTERN



( BW)(MO-TRIPOS)(TRPS) EMBL-DKFZ Joint Chemical Genomics FacilitySelects Tripos As Chemistry Partner in Quest for New Drug Discoveries

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS & BUDE, England--(BUSINESS WIRE)--July 20, 2004--Tripos,Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, has been selected by the EuropeanMolecular Biology Laboratory (EMBL) and the German Cancer ResearchCentre (DKFZ), to assist in rapid identification of potentialmolecular leads.
EMBL, a leading molecular biology research institute, and DKFZ, amember of the German Helmholtz Association of National ResearchCentres, jointly established one of the first European academicsmall-molecule screening facilities, in Heidelberg, Germany.
"Our strength in biology is matched by Tripos´ unique expertise inchemistry and small molecules, both areas in which we requireassistance," said Dr. Joe Lewis, head of the joint EMBL-DKFZ ChemicalGenomics Facility. "To get the best start we chose a chemistry partnerwho could provide a highly integrated design, synthesis andinformatics operation that reduces the time required at the earlystages of the discovery process. We see this as a long-term commitmentwith Tripos."
Tripos Discovery Research, Ltd. (TDR) will employ its chemistryknowledge base and associated knowledge-driven chemistry process tofacilitate rapid hit finding, hit follow-up and chemical optimizationof candidate molecules. "Using the right chemistry starting pointsenables us to shorten the hit-to-lead time frame and to minimizeproject attrition at later stages in the discovery process," said Dr.Peter Hecht, senior vice president of discovery research operationsand managing director of TDR, the United Kingdom-based discoverychemistry division of Tripos, Inc.

About Tripos

Tripos (Nasdaq:TRPS) combines cutting-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

About EMBL

The European Molecular Biology Laboratory is a basic researchinstitute funded by public research monies from 17 member states,including most of the E.U., Switzerland and Israel. Research at EMBLis conducted by approximately 80 independent groups covering thespectrum of molecular biology. The Laboratory has five units: the mainLaboratory in Heidelberg, and Outstations in Hinxton (the EuropeanBioinformatics Institute), Grenoble, Hamburg, and Monterotondo nearRome. The cornerstones of EMBL´s mission are: to perform basicresearch in molecular biology, to train scientists, students andvisitors at all levels, to offer vital services to scientists in themember states, and to develop new instruments and methods in the lifesciences. EMBL´s international PhD Programme has a student body ofabout 170. The Laboratory also sponsors an active Science and Societyprogramme. Visitors from the press and public are welcome.

About DKFZ

Task of the Deutsches Krebsforschungszentrum (German CancerResearch Centre, DKFZ) in Heidelberg is to investigate systematicallythe mechanisms of cancer development and to identify cancer riskfactors. The results of this basic research are expected to lead tonew approaches in the prevention, diagnosis and treatment of cancer.The centre is financed to 90 percent by the Federal Ministry ofEducation and Research (BMBF) and to 10 percent by the State ofBaden-Wuerttemberg. It is a member of the Helmholtz Association ofNational Research Centres (Helmholtz-Gemeinschaft DeutscherForschungszentren e.V., HGF).

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Tara Gajadhar, 425-638-7000, ext. 5073 (Media only) [e-mail] KEYWORD: MISSOURI UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MARKETINGAGREEMENTS SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 12:04 20.07.04

[Kautzie]

HRH The Duke of York Will Inaugurate New Research Facility At Tripos Discovery Research Centre
HRH The Duke of York Will Inaugurate New Research Facility At Tripos Discovery Research Centre

BW5197 JUL 22,2004 0:01 PACIFIC 03:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) HRH The Duke of York Will Inaugurate NewResearch Facility At Tripos Discovery Research Centre

Business Editors/Health/Medical Writers

ST. LOUIS & BUDE, England--(BUSINESS WIRE)--July 22, 2004--Tripos,Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced that His RoyalHighness (HRH) The Duke of York KVCO ADC will officiate at the openingof Tripos Discovery Research, Ltd.´s (TDR´s), new research facilityJuly 26 in Bude, England.
HRH The Duke of York has decided to visit the Tripos DiscoveryResearch Centre (TDRC) in his capacity as UK Special Representativefor International Trade and Investment. TDR, Queen´s Award forEnterprise winner in the category of International Trade in 2000 andthe Queen´s Award for Enterprise winner in the category of Innovationin 2003, created this state-of-the-art discovery chemistry facilitythat boasts over 65,000 square feet of laboratories and office space.The new TDRC facility is designed to meet increased demand created bythe continuing trend for outsourced research in the globalpharmaceutical industry and TDR´s expanding partnership base.
HRH The Duke of York will make an address during the openingceremony. He will also take a comprehensive tour of TDRC to gainfurther insight into the company´s knowledge-driven chemistry processthat highlights the power of integrated cheminformatics and syntheticchemistry.
"Tripos is proud to be a part of the Bude community and honoredthat His Royal Highness The Duke of York is participating in theinauguration ceremony at the Tripos Discovery Research Centre," saidDr. John McAlister, CEO and president of Tripos. "We´re excited aboutthe innovative research we are doing here as we continue to help ourcustomers transform their ideas into novel molecular entities thattreat diseases."
Formerly Receptor Research, Ltd, Tripos Discovery Research, Ltd.,was acquired by Tripos in 1997. Since its acquisition, theorganization has grown from 12 employees to over 170. TDR has workedwith the world´s leading pharmaceutical and biotechnology companies.

About Tripos

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--EH/se* CONTACT: Tripos, Inc. Lynne Trowbridge, [phone] or Waggener Edstrom Bioscience (Media only) Tara Gajadhar, 425-638-7073 [e-mail] KEYWORD: MISSOURI UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY PRODUCT SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 09:01 22.07.04

[Kautzie]

Tripos Announces Webcast of 2004 Second Quarter Financial Results
Tripos Announces Webcast of 2004 Second Quarter Financial Results

BW5142 JUL 23,2004 3:04 PACIFIC 06:04 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Announces Webcast of 2004 Second QuarterFinancial Results

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--July 23, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced it will conduct alive audio webcast presentation and conference call at 10 a.m. EDT onTuesday, July 27, to discuss quarterly financial results for theperiod ended June 30, 2004.
John P. McAlister, Ph.D., president and chief executive officer ofTripos; Jim Rubin, senior vice president and chief financial officer;and John Yingling, vice president and chief accounting officer, willhost the conference call. Tripos will announce its financial resultsfor the second quarter in a press release to be issued at 6 a.m. EDTthe same day. The press release and live webcast will be accessiblethrough the Tripos Web site at http://www.tripos.com/. The webcastwill be archived on the site starting at 1 p.m. EDT July 27 and willbe available there until Aug. 27.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore actual events,outcomes and results may differ materially from what is expressed orforecast in such forward-looking statements. We have identifiedcertain factors that could cause actual results to differ materiallyfrom the forward-looking statements in our Annual Report on Form 10-K,our Quarterly Reports on Form 10-Q, and our Current Reports on Form8-K. Except as otherwise required under federal securities laws andthe rules and regulations of the SEC, we do not have any intention orobligation to update or revise any forward-looking statements, whetheras a result of new information, future events, changes in assumptionsor otherwise.

--30--EH/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience (Media only) Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWARECONFERENCE CALLS EARNINGS SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:04 23.07.04

[matthiasch]

Tote Hose

Bei http://www.nano-invests.de/ gibt es weitere Infos.

[Kautzie]

Tripos Streamlines High-Throughput Screening Data Analysis With Release Of SARNavigator 1.5
Tripos Streamlines High-Throughput Screening Data Analysis With Release Of SARNavigator 1.5

BW5301 SEP 08,2004 3:01 PACIFIC 06:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Streamlines High-Throughput ScreeningData Analysis With Release Of SARNavigator 1.5

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Sept. 8, 2004--

New Software Application Rapidly Defines and Prioritizes Chemical Series for Follow-Up Screening

Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discoveryinformatics products and chemistry research, today announced therelease of SARNavigator(TM) 1.5, a new research application thatallows scientists to rapidly and objectively analyze the largequantities of chemical and biological data that comprise the resultsof real or virtual high-throughput screening. Using SARNavigator 1.5,researchers can rapidly identify and distinguish biologically activechemical series from the wealth of data contained in screeningresults, then effectively prioritize those series for furtherresearch, reducing traditional screening analysis timelines from weeksor months to hours or days.
"SARNavigator was collaboratively developed between Tripos and HTSdata analysis groups at several major pharmaceutical companies," saidDr. David Lowis, senior director of discovery software at Tripos. "Ithas been successfully deployed at a number of companies to identifyhigh-quality chemical series from high-throughput screeningexperiments for use in secondary screening and further chemicalexploration."

The new SARNavigator 1.5 release consists of three components:

--
SARNavigatorBASE(TM), a high-capacity chemical spreadsheet with substructure searching and chemical management capabilities, including descriptor calculation and analysis tools that include structure-activity relationships (SAR) table generation

--
SARNavigatorHQSAR(TM), a rapid, automated quantitative structure-activity relationships (QSAR) technique for creating predictive models and prioritizing chemical series from high-throughput data analysis

--
SARNavigatorHTS(TM), a complete tool set for the analysis of high-throughput screening (HTS) and virtual high-throughput screening data through novel and patented datamining algorithms (SAR Rules), and for visualization and exploration of entire SAR landscapes (SAR Maps), including definition, management and prioritization of chemical series

SARNavigator´s SAR Maps enable users to visualize all biologicallyrelevant chemical information from a high-throughput screen, while SARRules provide an automated method to locate likely chemical seriesbased on shared substructures. Combined, SAR Maps and SAR Rules allowresearchers to simultaneously navigate multidimensional molecularsimilarity spaces to locate the most promising series of compounds.This objective and versatile process enhances the success rate ofdownstream research by ensuring the best possible decisions are madeat the earliest stage of chemical research.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Tara Gajadhar, 425-638-7000, ext. 5073 (Media only) [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY SOFTWARE HARDWARE PRODUCT SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:01 08.09.04

[Kautzie]

Donnerstag, 30. September 2004 | 12:02 Uhr [Artikel versenden] [Artikel drucken] [zurück]
Tripos Amends and Extends Informatics Contract With Schering
Tripos Amends and Extends Informatics Contract With Schering

BW5171 SEP 30,2004 3:02 PACIFIC 06:02 EASTERN

( BW)(MO-TRIPOS/SCHERING)(TRPS)(SHR) Tripos Amends and ExtendsInformatics Contract With Schering

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS, Mo.--(BUSINESS WIRE)--Sept. 30, 2004--

New Agreement Covers Final Development Phase and Deployment Of Industry-Leading Enterprise Technology

Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discoveryinformatics products and chemistry research, today announced that ithas expanded its contract with Schering AG, Germany (NYSE:SHR) thatgoverns the companies´ ongoing discovery informatics collaboration onthe Enterprise Chemical Information Management System (ECIMS).
"The expanded Schering contract, which now also includes the finaldevelopment and deployment of the initial phase of the new system,provides Tripos with increased incremental funding that we believewill adequately cover our cost to complete the project," said Dr. JohnP. McAlister, president and chief executive officer at Tripos. "Thenew agreement includes scheduled development milestones withcompletion anticipated by mid-2005."
"Schering looks forward to continuing its long-standing,productive collaboration with Tripos and deploying ECIMS, which weview as an important advance in our drug discovery processes," saidProfessor Dr. Rainer Metternich, head of Research Center Europe atSchering.
When ECIMS 1.2 is deployed in 2005, it will allow Scheringscientists to manage their chemical research plans more efficiently,permitting them to access information from across the organization toprioritize experiments, avoid redundant experiments, and determinewhat materials they have on hand to use in their research process.
ECIMS uses the Tripos Electronic Notebook(TM) (TEN), theAUSPYX(TM) data cartridge and Tripos´ proprietary ChemCore(TM)technologies. Scientists enter their research plans, observations,results, analyses and conclusions in TEN, creating an integrated,searchable knowledge base. The AUSPYX technology allows them to searchand store different types of chemical structures without having toconsider variations in database architectures. And ChemCore, which isthe heart of the system, integrates library production processes,while tracking chemistry, chemicals and scientist activities. ECIMS isspecifically designed to improve workflow and increase collaborationacross teams throughout Schering´s global organization.
"ECIMS is a complex and ambitious undertaking, but through ourpartnership with Schering we have been able to create an informaticssolution unlike any other that has the power and potential tosignificantly impact the way research is being performed today. Welook forward to expanding our existing relationship with Schering andseeing the fruit of our labor in action," Dr. McAlister said.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos partners with clients to accelerateand improve the creation of life-enhancing products. Within Tripos´Discovery Informatics (DI) business, the company provides softwareproducts and consulting services to develop, manage, analyze and sharecritical drug discovery information. Within Tripos´ Discovery Research(DR) business, Tripos´ medicinal chemists and research scientistspartner directly with clients in their research initiatives,leveraging state-of-the-art information technologies and researchfacilities. Headquartered in St. Louis, Mo., Tripos spans the worldwith global research operations and an international client base.Further information on Tripos can be found at http://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--BRM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI GERMANY INTERNATIONAL EUROPE INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWAREHARDWARE MARKETING AGREEMENTS SOURCE: Tripos, Inc.

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:02 30.09.04

[Kautzie]

Hallo Matthiasch!

Stelle den Link wieder am Anfang des Threads. Denke das er hier am besten aufgehooben ist. Ansonsten geht er durch die Mitteilungen unter.

http://www.nano-invests.de/

Ich hoffe dies ist in allem Sinne

[Kautzie]

Tripos´ SYBYL 7.0 Discovery Software Suite Now Available; Molecular Modeling and Computational Chemistry Software for Drug Discovery
Tripos` SYBYL 7.0 Discovery Software Suite Now Available; Molecular Modeling and Computational Chemistry Software for Drug Discovery



BW5386 OCT 05,2004 5:04 PACIFIC 08:04 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos´ SYBYL 7.0 Discovery Software Suite NowAvailable; Molecular Modeling and Computational Chemistry Software forDrug Discovery

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Oct. 5, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery informaticsproducts and chemistry research, today announced the release ofSYBYL(R) 7.0, the latest version of its expert molecular modelingenvironment for drug discovery research. Tripos´ longstandingcustomer-focused approach enables the company to offer the newsoftware release on multiple platforms and includes a Linux operatingsystem upgrade, Red Hat Enterprise Linux 3.0. The new SYBYL softwarecontains numerous enhancements and expanded functionalities toexisting applications, and is available in DVD and CD-ROM formats.
The release supports mobile computing requirements forcomputational chemists with its expanded software licensingcapabilities for laptop computers. New "borrowable" SYBYL licensesallow laptop users to disconnect a set of licenses from their networklicense server, providing the flexibility to complete modelingactivities remotely. A white paper titled "Making In Silico DrugDiscovery Broadly Accessible: SYBYL on the IBM ThinkPad" describes theadvantages of laptop licensing and is available athttp://www.tripos.com/sybyl/laptop.html.
Tripos´ expanded technical support capabilities coincide with thenew SYBYL 7.0 software release. The company´s Technical Support OnlineWeb site, http://support.tripos.com, has been restructured andprovides instant access to numerous features and information,including a searchable knowledgebase, downloadable software scripts,immediate access to software patches and updates, and newproduct-specific sections relating to Tripos software.
"Tripos will uphold its tradition of industry leadership andcontinue to build upon its strong technology foundation by providingscientifically solid in silico solutions that reside in a trulyintegrated environment. Staying close to our customers and listeningcarefully to their needs enabled us to introduce the entire suite ofSYBYL products on Linux more than 18 months ago, and we are pleased tobe able to offer our customers the upgrade to Red Hat Enterprise Linux3.0," said Dr. Trevor Heritage, senior vice president and generalmanager of discovery informatics at Tripos.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com/.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--SAM/se* CONTACT: Tripos, Inc. Paul Wilhite, 314-647-1099 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL PRODUCT SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 14:04 05.10.04

[Kautzie]

Tripos Announces Webcast of 2004 Third-Quarter Financial Results
Tripos Announces Webcast of 2004 Third-Quarter Financial Results

BW5229 OCT 11,2004 3:01 PACIFIC 06:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Announces Webcast of 2004 Third-QuarterFinancial Results

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Oct. 11, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced it will conduct alive audio webcast presentation and conference call to discussquarterly financial results for the period ended Sept. 30, 2004, at 10a.m. EDT on Tuesday, Oct. 26.
John P. McAlister, Ph.D., president and chief executive officer,Jim Rubin, senior vice president and chief financial officer, and JohnYingling, vice president and chief accounting officer, will host theconference call. Tripos will announce its financial results for thethird quarter in a press release to be issued at 7 a.m. EDT the sameday. The press release and live webcast will be accessible through theTripos Web site at http://www.tripos.com. The webcast will be archivedon the site starting at 1 p.m. EDT on Oct. 26 and will be availablethere until Nov. 26.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--LL/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: SOFTWARE BIOTECHNOLOGY MEDICAL PHARMACEUTICALEARNINGS CONFERENCE CALLS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:01 11.10.04

[Kautzie]

Tripos Reports Third-Quarter 2004 Financial Results; Company Achieves Continued Sales Growth and Operating Profits
Tripos Reports Third-Quarter 2004 Financial Results; Company Achieves Continued Sales Growth and Operating Profits

BW5146 OCT 26,2004 3:02 PACIFIC 06:02 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Reports Third-Quarter 2004 FinancialResults; Company Achieves Continued Sales Growth and Operating Profits

Business Editors/Health Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Oct. 26, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced continuingimprovement in its financial results this year.
For the three months ended Sept. 30, 2004, those results includedthe following:

--
Tripos posted revenues of $16.1 million, a 16 percent increase from the previous year´s third-quarter revenues of $13.8 million.

--
Operating profit was $735,000, compared with an operating loss of $835,000 in the third quarter of 2003, an improvement of $1.6 million year over year.

--
Pretax income was $367,000, compared with pretax income of $1.7 million for the same period in 2003. Pretax income for the third quarter of 2003 included $1.5 million from the sale of shares of Arena Pharmaceuticals Inc. common stock.

--
Net loss was $145,000, or $0.02 per basic share, compared with income of $964,000, or $0.10 per diluted share, for the third quarter of 2003. The third-quarter 2004 tax rate included a valuation allowance for certain deferred tax assets. Third-quarter 2003 included $868,000 of after-tax gain, $0.09 per diluted share, from the sale of shares of Arena Pharmaceuticals.

For the nine months ended Sept. 30, 2004, the financials were asfollows:

-- Tripos posted revenues of $47.5 million, a 14 percent increase
from the previous year´s first nine-month revenues of $41.5
million.

-- Operating profit for this period in 2004 was $1.5 million,
compared with an operating loss of $3 million in the first
nine months of 2003, an improvement of $4.5 million year over
year.

-- Pretax income was $721,000, compared with pretax income of
$4.5 million for the same period in 2003. Pretax income in the
first nine months of 2003 included $6.1 million from the sale
of shares of Arena Pharmaceuticals.

-- Net loss was $14,000, or $0.00 per basic share after including
a valuation allowance for certain deferred tax assets in 2004.
This compares with net income of $2.5 million, or $0.27 per
diluted share, for the first nine months of 2003. The
nine-month period ended Sept. 30, 2003, included an after-tax
gain of $3.5 million or $0.37 per diluted share from the sale
of Arena stock.

"Consistent with our performance objectives for the year, Tripossuccessfully delivered double-digit revenue growth and recordedanother quarter of operating profitability," said Dr. John P.McAlister, president and CEO of Tripos. "This solid performance stemsfrom a concentration on operational efficiencies across our businessand from investments we have made over the past two years to developinnovative products and capabilities."

Third-Quarter Operational Highlights

Tripos announced the following strategic initiatives during thethird quarter:

-- Expanded contract with Schering AG related to the company´s
ongoing Tripos Discovery Informatics collaboration on the
Enterprise Chemical Information Management System (ECIMS). The
expanded contract includes the final development and
deployment of the initial phase of the new system and provides
Tripos with increased incremental funding.

-- Released SARNavigator(TM) 1.5, a new research application that
allows scientists to rapidly and objectively analyze the large
quantities of chemical and biological data that were the
result of real or virtual high-throughput screening.

-- Selected by the European Molecular Biology Laboratory (EMBL)
and the German Cancer Research Center (DKFZ) to assist in
rapid identification of potential molecular leads. EMBL, a
leading molecular biology research institute, and DKFZ, a
member of the Helmholtz Association of National Research
Centres, jointly established one of the first European
academic small-molecule screening facilities in Heidelberg,
Germany.

-- Established a new partnership with Divergence Inc., a leader
in the discovery of genomics-based solutions for the
prevention and treatment of parasitic infections, which will
bring drug discovery technologies to crop protection and
veterinary applications. Tripos will assist in the rapid
optimization of molecular leads discovered by Divergence.

-- Formally opened Tripos Discovery Research Ltd.´s (TDR´s) new
research facility in Bude, England, with His Royal Highness
the Duke of York KCVO ADC officiating. The new TDR facility is
designed to meet increased demand created by the continuing
trend for outsourced research in the global pharmaceutical
industry and TDR´s expanding partnership base.

Webcast Information

Tripos will host a conference call and webcast today at 10 a.m.EDT to discuss these financial results in detail. Those who want toparticipate in the webcast should visit the Tripos Web site athttp://www.tripos.com. An archived copy of the Tripos webcast will beavailable beginning at 1 p.m. EDT today, and will remain on the TriposWeb site through Nov. 26.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

Tripos, Inc. Condensed Results of Operations (in thousands, except per-share data) Three Months Ended Nine Months Ended ------------------- ------------------- 30-Sep-04 30-Sep-03 30-Sep-04 30-Sep-03Net sales Restated Restated Discovery software products and support $ 6,005 $ 5,779 $ 18,225 $ 17,611 Discovery informatics services 1,247 759 2,681 3,034 Discovery research products and services 8,824 7,154 26,459 20,105 Hardware 24 152 98 781 ------------------ ------------------Total net sales 16,100 13,844 47,463 41,531 Cost of sales 8,333 6,236 23,435 18,768 ------------------ ------------------Gross profit 7,767 7,608 24,028 22,763Operating expenses Sales and marketing 3,089 3,260 9,464 9,901 Research and development 2,140 3,369 7,433 10,200 General and administrative 1,803 1,814 5,585 5,646 ------------------ ------------------Total operating expenses 7,032 8,443 22,482 25,747Income (loss) from operations 735 (835) 1,546 (2,984) Other income (loss), net (368) 2,521 (825) 7,445 ------------------ ------------------Income before income taxes 367 1,686 721 4,461 Income tax expense 512 722 735 1,909 ------------------ ------------------Net income $ (145) $ 964 $ (14) $ 2,552 ================== ==================Basic income per share $ (0.02) $ 0.11 $ (0.00) $ 0.29Diluted income per share $ (0.02) $ 0.10 $ (0.00) $ 0.27Basic weighted average shares 9,290 8,988 9,170 8,934Diluted shares outstanding 9,290 9,459 9,170 9,310 Tripos, Inc. Consolidated Balance Sheets (in thousands, except per-share data) 30-Sep-2004 31-Dec-2003 UnauditedAssets:Current assets: Cash and cash equivalents $ 4,768 $ 2,945 Marketable securities 49 1,121 Accounts receivable 10,391 16,662 Inventory 11,873 12,863 Deferred income taxes 419 -- Prepaid expenses 2,870 5,054 -------------------- Total current assets 30,370 38,645Property and equipment, less accumulated depreciation 29,376 27,926Capitalized development costs, net 2,420 2,417Goodwill 965 965Investments recorded at cost 1,482 1,352Deferred income taxes -- --Other, net 181 390 -------------------- Total assets $ 64,794 $ 71,695 ====================Liabilities and shareholders´ equity:Current liabilities: Current portion of long-term debt and capital leases $ 3,617 $ 10,510 Accounts payable 1,576 2,405 Accrued expenses 4,235 7,688 Deferred revenue 18,804 17,079 Deferred income taxes -- 219 -------------------- Total current liabilities 28,232 37,901Long-term portion of capital leases 3,579 2,463Long-term debt 3,752 3,915Deferred income taxes 967 422Shareholders´ equity Common stock 47 45 Additional paid-in capital 37,142 36,502 Retained earnings (deficit) (8,336) (8,321) Other comprehensive income (deficit) (589) (1,232) -------------------- Total shareholders´ equity 28,264 26,994 Total liabilities and shareholders´ equity $ 64,794 $ 71,695 ====================

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 (Media only) [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL EARNINGS CONFERENCECALLS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:02 26.10.04

[Kautzie]

Tripos and NovaScreen Combine Technologies for Strida Pharma in Search of Compounds to Fight Cancer; Collaboration Joins Two Fields of Science and Gains Momentum
Tripos and NovaScreen Combine Technologies for Strida Pharma in Search of Compounds to Fight Cancer; Collaboration Joins Two Fields of Science and Gains Momentum

BW5048 NOV 09,2004 4:01 PACIFIC 07:01 EASTERN

( BW)(MO-TRIPOS/NOVASCREEN)(TRPS) Tripos and NovaScreen CombineTechnologies for Strida Pharma in Search of Compounds to Fight Cancer;Collaboration Joins Two Fields of Science and Gains Momentum

Health/Medical Writers/Biotech Writers
BIOWIRE2K

ST. LOUIS and HANOVER, Md.--(BUSINESS WIRE)--Nov. 9, 2004--Tripos,Inc. (Nasdaq:TRPS), and NovaScreen Biosciences Corporation haveannounced a joint collaboration to provide a complete drug discoverysolution to Strida Pharma Inc. of Montreal in support of Strida´scancer therapeutics development program focused around the company´sstrategic target, Methylenetetrahydrofolate Reductase (MTHFR).
Launched in August 2004, the collaboration brings together Tripos´knowledge-driven chemistry expertise and NovaScreen´s assaydevelopment and biological screening capabilities to provide Stridawith industry-leading drug discovery support. Tripos will identify,design and synthesize suitable compounds for biological activityassessment in a high-throughput MTHFR assay developed by NovaScreen.Tripos and NovaScreen will work together to develop primary screeninghits to potential lead compounds.
"Tripos and NovaScreen offer the advantages of first-classchemical and biological research expertise. Their combined effortswill rapidly deliver promising small molecules for MTHFR-based cancertreatment and help us bring new drug candidates to clinical trials,"said Dr. Rima Rozen, president and founder of Strida Pharma.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines cutting-edge technology andinnovative science to deliver leading chemistry-research products andservices for the biotechnology, pharmaceutical and other life scienceindustries. Headquartered in St. Louis, Mo., Tripos spans the worldwith global research operations and an international client base.www.tripos.com.

About NovaScreen Biosciences Corporation

NovaScreen Biosciences Corporation (www.novascreen.com) is aleading provider of drug discovery and development services andproducts, with a focus on in vitro (laboratory-based) screening assaysand in silico (computer-based) predictive screening tools. With morethan 10 years of operating history, NovaScreen is widely recognized asa pioneer in the field of receptor pharmacology, with particularexpertise in G-Protein Coupled Receptors and other molecular targetsthat mediate disease states and side effects in the central nervoussystem. NovaScreen´s core competencies extend to side effect andtherapeutic targets across the major organ systems and disease areas,and include assay development, discovery (high throughput) screening,selectivity screening, profiling, in vitro toxicology, and in vitropharmacokinetics. NovaScreen has developed and routinely performs morethan 350 receptor, enzyme, ion channel, transporter, and cell-basedscreening assays relevant to the discovery of new drugs and/or theselection and optimization of new drug candidates. Services andproducts are provided to more than 180 clients worldwide, including amajority of the leading drug and biotechnology companies.www.novascreen.com.

About Strida Pharma, Inc.

Strida Pharma Inc. is a spin-off company of McGill University(Montreal, Canada) that was founded in 2002 through an investment byMedTech Partners (www.medtechpartners.com). Strida is developing smallmolecule therapeutics based on the methylenetetrahydrofolate reductase(MTHFR) enzyme. MTHFR is a strategic target for anti-cancer therapy,based on its critical role in folate metabolism and methioninesynthesis, since a broad range of tumors are known to bemethionine-dependent. Strida has recently validated MTHFR as ananti-cancer target in animal models, using antisense technologies, andhas been seeking to partner the creation of a high-throughput assayfor the identification of small molecule inhibitors of MTHFR fordevelopment of promising drug candidates.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--LL/se* CONTACT: Tripos, Inc. Jim Rubin, 314/647-8837 Chief Financial Officer or NovaScreen Biosciences Corporation Richard Hellmer, 410/712-4410 (office) 410/499-0880 (mobile) Director of Business Development [e-mail] or Strida Pharma Inc. Marc Lussier, Ph.D., 514/376-9321 (office) 514/830-5143 (mobile) Chief Executive Officer [e-mail] or Waggener Edstrom Bioscience (Media only) Tara Gajadhar, 425/638-7000, ext. 5073 Senior Account Executive [e-mail] KEYWORD: MARYLAND MISSOURI INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL MARKETINGAGREEMENTS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 13:01 09.11.04

[Kautzie]

Tripos and Pfizer Sign Multiyear Renewal of Global Software License
Tripos and Pfizer Sign Multiyear Renewal of Global Software License

BW5256 NOV 15,2004 4:01 PACIFIC 07:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos and Pfizer Sign Multiyear Renewal ofGlobal Software License

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Nov. 15, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery informaticsproducts and chemistry research, has announced a multimillion-dollar,multiyear extension of its global software license agreement withPfizer Inc. (NYSE:PFE).
Tripos´ discovery software is used by customers to manage, analyzeand share biological and chemical information. Since the two companiesannounced their first wide area network (WAN) partnership in January2001, Pfizer has employed a broad array of Tripos´ proprietary drugdiscovery software tools and applications, including theindustry-leading SYBYL(R) and UNITY(R) programs, which help totransform science into commercially viable products.
"For more than 18 years, Pfizer has used Tripos´ computationaltechnology to enhance its drug discovery efforts," said Dr. TrevorHeritage, senior vice president and general manager of DiscoveryInformatics for Tripos. "We are delighted that Pfizer has chosen toenlarge and extend its commitment to our products, and we look forwardto our ongoing work with Pfizer."

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior,chemistry-research products and services for the biotechnology,pharmaceutical and other life science industries. Tripos collaborateswith clients to accelerate and improve the creation of life-enhancingproducts. Within Tripos´ Discovery Informatics (DI) business, thecompany provides software products and consulting services to develop,manage, analyze and share critical drug discovery information. WithinTripos´ Discovery Research (DR) business, Tripos´ medicinal chemistsand research scientists partner directly with clients in theirresearch initiatives, leveraging state-of-the-art informationtechnologies and research facilities. Headquartered in St. Louis, Mo.,Tripos spans the world with global research operations and aninternational client base. Further information on Tripos can be foundat http://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--BRM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Tara Gajadhar, 425-638-7000, ext. 5073 (Media only) [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: HARDWARE NETWORKING SOFTWARE BIOTECHNOLOGYCHEMICALS/PLASTICS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[Kautzie]

Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership
Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership

BW5270 NOV 30,2004 4:03 PACIFIC 07:03 EASTERN

( BW)(MO-TRIPOS)(TRPS) Sanofi-Synthelabo Recherche Selects Tripos forDrug Discovery Partnership

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Nov. 30, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced that it has entereda strategic partnership with Sanofi-Synthelabo Recherche, an affiliateof Sanofi-Aventis (NYSE:SNY).
Sanofi-Synthelabo Recherche has identified a number of proprietarychemistry motifs that exhibit therapeutic potential in a wide range oftarget areas. Tripos will employ its knowledge-driven chemistryapproach to design and synthesize compounds that expand these areas.Tripos´ high-throughput medicinal chemistry process will enable therapid synthesis of those compounds to meet Sanofi-SynthelaboRecherche´s project time frame requirements.
"Tripos has long recognized the positive impact that high-qualitystarting points have on the drug discovery process," said Dr. John P.McAlister, president and chief executive officer at Tripos. "Our aimis to enable Sanofi-Synthelabo Recherche to minimize time andattrition in the early phases of drug discovery by designing startingpoints that are structurally desirable and developable."
"Sanofi-Synthelabo Recherche required a partner who could meet ourexacting project criteria of quality, quantity, structuraldesirability and speed of delivery," said Philippe Bovy, manager ofchemical estate at Sanofi-Synthelabo Recherche. "Tripos´ integratedapproach to compound design and synthesis, in conjunction with itsproven experience in this area, made it the partner of choice."

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: SOFTWARE BIOTECHNOLOGY PHARMACEUTICAL MARKETINGAGREEMENTS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

[Kautzie]

Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership
Sanofi-Synthelabo Recherche Selects Tripos for Drug Discovery Partnership

BW6088 DEC 01,2004 23:02 PACIFIC 02:02 EASTERN

( BW)(MO-TRIPOS)(TRPS) Sanofi-Synthelabo Recherche Selects Tripos forDrug Discovery Partnership

Business Editors/Health/Medical Writers

ST. LOUIS--(BUSINESS WIRE)--Dec. 1, 2004--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced that it has entereda strategic partnership with Sanofi-Synthelabo Recherche, an affiliateof Sanofi-Aventis (NYSE:SNY).
Sanofi-Synthelabo Recherche has identified a number of proprietarychemistry motifs that exhibit therapeutic potential in a wide range oftarget areas. Tripos will employ its knowledge-driven chemistryapproach to design and synthesize compounds that expand these areas.Tripos´ high-throughput medicinal chemistry process will enable therapid synthesis of those compounds to meet Sanofi-SynthelaboRecherche´s project time frame requirements.
"Tripos has long recognized the positive impact that high-qualitystarting points have on the drug discovery process," said Dr. John P.McAlister, president and chief executive officer at Tripos. "Our aimis to enable Sanofi-Synthelabo Recherche to minimize time andattrition in the early phases of drug discovery by designing startingpoints that are structurally desirable and developable."
"Sanofi-Synthelabo Recherche required a partner who could meet ourexacting project criteria of quality, quantity, structuraldesirability and speed of delivery," said Philippe Bovy, manager ofchemical estate at Sanofi-Synthelabo Recherche. "Tripos´ integratedapproach to compound design and synthesis, in conjunction with itsproven experience in this area, made it the partner of choice."

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--BRM/se* CONTACT: Tripos, Inc. Jim Rubin, 1-314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 1-425-638-7134 [e-mail] KEYWORD: MISSOURI UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: SOFTWARE BIOTECHNOLOGY PHARMACEUTICALCHEMICALS/PLASTICS MARKETING AGREEMENTS SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 08:02 01.12.04

[Kautzie]

Tripos Announces Agreement to Acquire Optive Research, a Molecular Discovery Software Company
Tripos Announces Agreement to Acquire Optive Research, a Molecular Discovery Software Company



BW5107 DEC 22,2004 3:01 PACIFIC 06:01 EASTERN



( BW)(MO-TRIPOS)(TRPS) Tripos Announces Agreement to Acquire OptiveResearch, a Molecular Discovery Software Company

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Dec. 22, 2004--


Expands Product Portfolio to Provide Customers With a Broader Range of Innovative Informatics Solutions

Tripos, Inc. (Nasdaq:TRPS), today announced that it has enteredinto a definitive agreement to acquire privately held Optive Research,Inc., a recognized leader in developing innovative software forcomputer-assisted molecular discovery. This acquisition expandsTripos´ ability to enable its biotechnology, pharmaceutical andrelated life science customers to bring new drugs and other importantchemical compounds to market faster and more efficiently.
Under the terms of the agreement, Tripos will issue 599,521 sharesof its common stock (a portion of which will be contractuallyrestricted) and $4.75 million in cash to Optive´s shareholders. Thecash portion will be funded by a group of new investors through theissuance of $3.5 million of subordinated debt, 111,606 shares ofcommon stock, and warrants to purchase 156,250 shares of common stock.The acquisition is subject to certain closing conditions and isexpected to close in January 2005. Tripos expects the transaction tobegin to contribute to operating income in 2005, and become accretiveto net income beginning in 2006.
Tripos has been a worldwide distributor of software developed byDr. Robert S. Pearlman at the University of Texas at Austin since1987, and that relationship continued when Dr. Pearlman formed OptiveResearch as a technology spinout from the university in 2002. Softwaredeveloped by Optive´s scientists is now in use at nearly every majorpharmaceutical company in the world.
This acquisition, combined with Tripos´ recent expansion of itsU.K.-based, knowledge-driven chemistry research facility -- the TriposDiscovery Research Centre -- serves to reinforce the company´s growthstrategy. Furthermore, it demonstrates Tripos´ ongoing commitment toprovide its customers with a full range of scientifically advancedproducts and services to improve chemistry research processes.
"We are actively seeking opportunities in all areas of ourbusiness to drive the next level of the company´s growth," said Dr.John P. McAlister, president and chief executive officer for Tripos."The acquisition of Optive adds important new products, key enablingtechnologies and world-renowned scientific expertise to our softwarebusiness, allowing Tripos to offer an even broader array of innovativeinformatics solutions to its customers."
Tripos currently distributes five of more than 15 products inOptive´s software portfolio, including DiverseSolutions(TM),StereoPlex(TM) and Concord(TM), the industry´s leading program forcreating three-dimensional chemical models. These and other Optiveproducts and enabling technologies complement Tripos´ existingsoftware portfolio to provide solutions that further address theunique needs of computational scientists, laboratory or "bench"scientists, and other informaticians involved in chemistry researchand development.
"Tripos´ synergistic software portfolio, global sales andmarketing channels, and proven customer support capabilities, combinedwith Optive´s products, scientists and ongoing business relationshipswith key partners, constitute a powerful platform from which toadvance chemistry research throughout the world," said Bryan Koontz,chief executive officer for Optive Research.
"Optive and Tripos share a common vision for scientific excellenceand ongoing innovation in discovery research," said Dr. Pearlman,chairman and chief scientific officer for Optive. "We look forward tobuilding on our long-standing relationship with Tripos and merging ourcombined strengths to bring to market many exciting solutions and newopportunities for our joint customer base."
Following the close of the transaction, Dr. Pearlman will remainat the University of Texas, but will play an active role as aconsultant and scientific advisor to Tripos. Mr. Koontz will joinTripos´ Discovery Informatics executive team as vice president ofcorporate development. Other key Optive Research employees will joinTripos´ Discovery Informatics business.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

About Optive Research, Inc.

Optive Research develops, markets and supports life sciencesoftware solutions that help companies engaged in molecular discoveryresearch bring beneficial chemical compounds to market faster, whilereducing overall cost. Optive´s novel software is designed for bothcomputational chemists and experimental, "wet-lab" scientists,enabling them to reduce discovery cycle times and synthesizehigher-quality lead compounds, thereby achieving more predictablediscovery and development processes. Software developed by OptiveResearch is currently in use at nearly every major pharmaceuticalcompany and at hundreds of other research sites worldwide. Moreinformation about Optive Research is available athttp://www.optive.com.

This press release includes statements that are not historical innature and that may be characterized as "forward-looking statements,"including those related to future financial and operating results,benefits and synergies of the company´s brands and strategies, andfuture opportunities. You should be aware that Tripos´ actual resultscould differ materially from those contained in the forward-lookingstatements, which are based on current expectations of Triposmanagement and are subject to a number of risks and uncertainties,including, but not limited to, Tripos´ ability to integrate acquiredoperations and employees, Tripos´ success in executing its businessstrategies, other business conditions and the general economy, marketopportunities, potential new business strategies, competitive factors,sales and marketing execution, shifts in technologies or marketdemand, and the other factors described in Tripos´ Annual Report onForm 10-K for the 2003 fiscal year. Tripos disclaims any intention orobligation to update any forward-looking statements as a result ofdevelopments occurring after the date of this press release.
Tripos and the Tripos logo are registered trademarks of Tripos,Inc. and/or its affiliates in the U.S. and certain other countries.All other trademarks mentioned in this document are the property oftheir respective owners.

--30--LL/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWAREMERGERS/ACQ SOURCE: Tripos, Inc.Copyright Business Wire 2004

(c) 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.



Autor: © Business Wire , 12:01 22.12.04

[Kautzie]

http://www.nano-invests.de/

[Kautzie]

Tripos Completes Acquisition of Optive Research, a Molecular Discovery Software Company
Tripos Completes Acquisition of Optive Research, a Molecular Discovery Software Company

BW5355 JAN 05,2005 3:02 PACIFIC 06:02 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Completes Acquisition of OptiveResearch, a Molecular Discovery Software Company

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Jan. 5, 2005--

Acquisition Expands Software Portfolio and Provides Access to Pipeline of Innovative New Products

Tripos, Inc. (Nasdaq:TRPS), today announced that it has acquiredprivately held Optive Research, Inc., a recognized leader indeveloping innovative software for computer-assisted moleculardiscovery, for $4.75 million in cash and 599,521 shares of Triposstock.
The cash portion of the deal was funded through a $4 millioninvestment by Horizon Technology Finance, LLC and Sand Hill Capitalthrough the issuance of $3.5 million of subordinated debt, 111,606shares of common stock, and warrants to purchase 156,250 shares ofcommon stock. Tripos expects this transaction to begin contributing toits operating income in 2005, and become accretive to net income by2006. Seven Hills Partners acted as exclusive placement agent toTripos in arranging this financing.
"This acquisition provides Tripos with full access to OptiveResearch´s existing cheminformatics products in addition to itspipeline of new offerings and technologies," said Dr. John P.McAlister, president and chief executive officer for Tripos. "It isadditive to Tripos´ current and future software portfolio, whileenlarging our staff through addition of key Optive scientists whosecomplementary expertise augments our own core strengths."
"This transaction is another step in our growth strategy, enablingus to continue to deliver innovative products and capabilities thatenhance the chemistry research process while assisting our customersto take their new products to market faster and more efficiently," Dr.McAlister said.
Several examples of the new Optive products include Benchware(TM),a suite of desktop tools for combinatorial library enumeration, designand analysis; EA-Inventor, a novel program for de novo moleculardesign; and innovative technology for uniquely and accuratelyrepresenting the tautomeric and stereochemical structures of chemicalcompounds as they can exist under various natural conditions.Benchware products complement and will be integrated with Tripos´LITHIUM(TM) technology during the next 12 months. Similarly, Triposwill incorporate key Optive technologies within its variouscheminformatics and molecular modeling products and plans to exploremutually beneficial arrangements around these technologies with othersoftware providers.
"This deal leverages the strengths of both companies and offers awin-win situation for our joint customer base," said Bryan Koontz,former chief executive officer for Optive Research. "We have combinedthe companies´ synergistic software portfolios and scientificexpertise, added Tripos global sales and marketing channels andcustomer support capabilities and Optive´s business partnerships tocreate the optimal cheminformatics partner for chemistry researchersworldwide."
Mr. Koontz is joining Tripos as vice president of corporatedevelopment for Discovery Informatics, bringing with him a wealth ofmarketing, business development and alliance management experience. Henow reports to Dr. Trevor Heritage, senior vice president and generalmanager of Discovery Informatics. Professor Robert S. Pearlman, formerchairman and chief scientific officer for Optive, is remaining at theUniversity of Texas, but will serve as a consultant and scientificadvisor to Tripos. In addition, Optive´s key scientists and developershave joined Tripos´ Discovery Informatics business. The former Optiveemployees will continue to work out of Austin, Texas.
"I have worked with Tripos for more than 17 years, and I continueto be impressed by their in-depth knowledge of drug discovery researchand their dedication to delivering innovative computer-assistedmolecular discovery technologies to their customers andcollaborators," Professor Pearlman said. "I look forward to buildingon our existing relationship, and I am confident that our customersare in good hands."
Tripos has been a worldwide distributor of Professor Pearlman´ssoftware since 1987, first directly through the University of Texas atAustin and then indirectly through Optive Research, which ProfessorPearlman formed as a technology spinout from the university in 2002.Tripos currently distributes five of Optive´s 15 products, includingDiverseSolutions(TM), StereoPlex(TM) and Concord(TM), the industry´sleading program for creating three-dimensional chemical models.

Webcast Information

Tripos will host a conference call and webcast today at 1 p.m. ESTto discuss this acquisition in detail. Participants will include Dr.McAlister, Dr. Heritage, Professor Pearlman, Mr. Koontz and Jim Rubin,chief financial officer and senior vice president at Tripos. Those whowant to participate in the webcast should visit the Tripos Web site athttp://www.tripos.com. An archived copy of the Tripos webcast will beavailable beginning at 4 p.m. EST today, and will remain on the TriposWeb site through Feb. 5.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

About Optive Research, Inc.

Optive Research develops, markets and supports life sciencesoftware solutions that help companies engaged in molecular discoveryresearch bring beneficial chemical compounds to market faster, whilereducing overall cost. Optive´s novel software is designed for bothcomputational chemists and experimental, "wet-lab" scientists,enabling them to reduce discovery cycle times and synthesizehigher-quality lead compounds, thereby achieving more predictablediscovery and development processes. Software developed by OptiveResearch is currently in use at nearly every major pharmaceuticalcompany and at hundreds of other research sites worldwide. Moreinformation about Optive Research is available athttp://www.optive.com.

This press release includes statements that are not historical innature and that may be characterized as "forward-looking statements,"including those related to future financial and operating results,benefits and synergies of the company´s brands and strategies, andfuture opportunities. You should be aware that Tripos´ actual resultscould differ materially from those contained in the forward-lookingstatements, which are based on current expectations of Triposmanagement and are subject to a number of risks and uncertainties,including, but not limited to, Tripos´ ability to integrate acquiredoperations and employees, Tripos´ success in executing its businessstrategies, other business conditions and the general economy, marketopportunities, potential new business strategies, competitive factors,sales and marketing execution, shifts in technologies or marketdemand, and the other factors described in Tripos´ Annual Report onForm 10-K for the 2003 fiscal year. Tripos disclaims any intention orobligation to update any forward-looking statements as a result ofdevelopments occurring after the date of this press release.

Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.

--30--SAM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Media only: Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI TEXAS INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWAREMERGERS/ACQ CONFERENCE CALLS SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:02 05.01.05

[Kautzie]

BioTie Therapies Chooses Tripos as Strategic Chemistry Partner in Drug Discovery
BioTie Therapies Chooses Tripos as Strategic Chemistry Partner in Drug Discovery

BW5244 FEB 07,2005 3:01 PACIFIC 06:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) BioTie Therapies Chooses Tripos as StrategicChemistry Partner in Drug Discovery

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS & TURKU, Finland--(BUSINESS WIRE)--Feb. 7, 2005--Tripos,Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, and BioTie Therapies Corp., aFinnish biotech company, have announced a partnership to enhanceBioTie´s drug discovery efforts, which include innovative medicinesfor the treatment of dependence disorders, inflammatory diseases andthrombosis.
Under the agreement, Tripos will identify and optimize backupseries for one of BioTie´s key drug discovery programs. Tripos´LeadHopping(TM) technology is essential to identifying structurallydistinct, though shape-similar, compounds whose chemistry is unrelatedto that of the original lead and therefore free of patentrestrictions. Tripos will then rapidly create compound libraries forin-house screening by BioTie.
Financial terms of the multiyear agreement were not disclosed.
"Tripos demonstrated its outstanding computational drug designcapabilities in a pilot project, and we were impressed with itsability to quickly transform virtual chemistry into viable,high-quality screening. Those capabilities drove our selection ofTripos as our chemistry partner to accelerate BioTie´s drug discoverytimelines," said Jari Saarinen, BioTie president and CEO.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

About BioTie Therapies Corp.

BioTie Therapies Corp. (HEX:BTH1V) is a public Finnish biotechcompany specializing in pharmaceutical product development. Its mainfocus is on products for the treatment of dependence disorders,inflammatory diseases and thrombosis. For more information, pleasevisit http://www.biotie.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.

--30--SAM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Media only: Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI FINLAND INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE PRODUCTMARKETING AGREEMENTS SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:01 07.02.05

[Kautzie]

Tripos Promotes Dr. Mark Allen to Senior Vice President and Managing Director of Tripos Discovery Research Ltd.
Tripos Promotes Dr. Mark Allen to Senior Vice President and Managing Director of Tripos Discovery Research Ltd.

BW5268 FEB 07,2005 3:01 PACIFIC 06:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Promotes Dr. Mark Allen to Senior VicePresident and Managing Director of Tripos Discovery Research Ltd.

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS & BUDE, England--(BUSINESS WIRE)--Feb. 7, 2005--Tripos,Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced that it haspromoted Mark Allen, Ph.D., to senior vice president and managingdirector of Tripos Discovery Research, Ltd. (TDR). In his new role,Dr. Allen is responsible for Tripos´ Discovery Research business.
"Mark continues his distinguished career at Tripos as a highlyvalued member of our executive team. He is a strong leader, bringingvision, strategic thinking, and more than 30 years´ experience runningresearch and development operations not only at TDR, but also atNovartis and Ciba Pharma UK," said Dr. John P. McAlister, presidentand chief executive officer of Tripos.
Dr. Allen succeeds Dr. Peter Hecht, who is leaving Tripos tobecome chief executive officer of Oridis Biomed GmbH. This Austriantissue genomics company focuses on the disease-based medicalvalidation of targets and initial stages of development to reduceattrition rates in discovery and clinical development. Dr. Hecht willcontinue to work with Tripos as a scientific advisor to the company.
"Peter´s move is a very amicable one. Oridis and Tripos have beencollaborating on Parallel Optimization of Novel Targets, a projectfunded by the European Union for the rapid identification andoptimization of novel targets and novel chemistries, since December2003," Dr. McAlister said. "This project also demonstrates the commonstrategic vision of Tripos and Oridis: how to reduce attrition ratesby means of a knowledge-driven approach from disease to drug."
Dr. Allen joined Tripos in 1998 as director of research andanalytics and deputy managing director of Tripos Receptor ResearchLtd. (now Tripos Discovery Research, Ltd.). A year later, he waspromoted to vice president of operations, where he managed allscientific activities for Tripos´ Discovery Research business,including research, design, high-throughput chemistry production,analytics, and compound purification and processing.
Previously, Dr. Allen was head of drug discovery support forNovartis Pharma UK, where he oversaw chemical analytics, chemistrydevelopment and scale-up synthesis. He originally joined CIBA-GeigyPharma UK, Ltd., in 1975, and after a series of promotions wasappointed head of core drug technologies for CIBA Pharma UK in 1994.Following the formation of Novartis in 1997, he was named head of drugdiscovery support for Novartis Pharma UK.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Within Tripos´ Discovery Informatics (DI)business, the company provides software products and consultingservices to develop, manage, analyze and share critical drug discoveryinformation. Within Tripos´ Discovery Research (DR) business, Tripos´medicinal chemists and research scientists partner directly withclients in their research initiatives, leveraging state-of-the-artinformation technologies and research facilities. Further informationon Tripos can be found at http://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.

--30--SAM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Media only: Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI AUSTRIA UNITED KINGDOM INTERNATIONAL EUROPE INDUSTRY KEYWORD: PHARMACEUTICAL BIOTECHNOLOGY SOFTWARE MANAGEMENTCHANGES SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:01 07.02.05

[Kautzie]

Tripos Announces Webcast of Fourth-Quarter and Full-Year 2004 Financial Results
Tripos Announces Webcast of Fourth-Quarter and Full-Year 2004 Financial Results

BW5333 FEB 08,2005 3:02 PACIFIC 06:02 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos Announces Webcast of Fourth-Quarter andFull-Year 2004 Financial Results

Business Editors/Health/Medical Writers
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Feb. 8, 2005--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced it will conduct alive audio webcast presentation and conference call to discussfinancial results for the fourth quarter and full year ended Dec. 31,2004, at 10 a.m. EST on Tuesday, Feb. 22.
John P. McAlister, Ph.D., president and chief executive officer ofTripos; Jim Rubin, senior vice president of finance and chieffinancial officer of Tripos; and John Yingling, vice president andchief accounting officer of Tripos, will host the conference call.Tripos will announce its financial results for the fourth quarter andfull year 2004 in a press release to be issued at 6 a.m. EST the sameday. The press release and live webcast will be accessible through theTripos Web site at http://www.tripos.com. The webcast will be archivedon the site starting at 1 p.m. EST on Feb. 22 and will be availablethere until March 22.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

--30--SAM/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY SOFTWAREEARNINGS CONFERENCE CALLS SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:02 08.02.05

[Kautzie]

Tripos President and CEO Will Present at The Wall Street Analyst Forum
Tripos President and CEO Will Present at The Wall Street Analyst Forum

BW5113 FEB 21,2005 3:01 PACIFIC 06:01 EASTERN

( BW)(MO-TRIPOS)(TRPS) Tripos President and CEO Will Present at TheWall Street Analyst Forum

Business Editors/Health/Medical Writers
16th Annual Wall Street Analyst Forum
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Feb. 21, 2005--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced that President andChief Executive Officer Dr. John P. McAlister will present at The WallStreet Analyst Forum on Monday, Feb. 28, 2005, at 10:20 a.m. EST. Thepresentation will take place at The Roosevelt Hotel in New York.

Who: Dr. John P. McAlister, president and CEO of TriposWhat: The Wall Street Analyst ForumWhere: The Roosevelt Hotel in New YorkWhen: Monday, Feb. 28, 2005, at 10:20 a.m. EST

In addition, the company´s audio webcast can be accessed athttp://www.vcall.com/cepage.asp?id=90649.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Within Tripos´ Discovery Informatics (DI)business, the company provides software products and consultingservices to develop, manage, analyze and share critical drug discoveryinformation. Within Tripos´ Discovery Research (DR) business, Tripos´medicinal chemists and research scientists partner directly withclients in their research initiatives, leveraging state-of-the-artinformation technologies and research facilities. Further informationon Tripos can be found at http://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.

Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.

--30--APG/se* CONTACT: Tripos, Inc. Jim Rubin, 314-647-8837 or Media only: Waggener Edstrom Bioscience Lisa Osborne, 425-638-7134 [e-mail] KEYWORD: MISSOURI NEW YORK TRACK INDUSTRY KEYWORD: BIOTECHNOLOGY TRADESHOW SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:01 21.02.05

[Kautzie]

Tripos Reports Fourth Quarter and Full Year 2004 Financial Results; Company Delivers Solid Revenue Growth and Return to Profitability
Tripos Reports Fourth Quarter and Full Year 2004 Financial Results; Company Delivers Solid Revenue Growth and Return to Profitability

BW5434 FEB 22,2005 3:02 PACIFIC 06:02 EASTERN

( BW)(MO-TRIPOS-INC)(TRPS) Tripos Reports Fourth Quarter and Full Year2004 Financial Results; Company Delivers Solid Revenue Growth andReturn to Profitability

Business Editors/Medical Editors
BIOWIRE2K

ST. LOUIS--(BUSINESS WIRE)--Feb. 22, 2005--Tripos, Inc.(Nasdaq:TRPS), a leading provider of drug discovery chemistry andinformatics products and services, today announced financial resultsfor the fourth quarter and full year ended Dec. 31, 2004.
"2004 was a successful turnaround year for Tripos. We achievedsolid revenue growth along with a return to profitability and strongcash flows from operations," said Dr. John P. McAlister, president andchief executive officer of Tripos. "In addition, 2004 included anumber of meaningful events for Tripos. We began the year with thecompletion of our expanded discovery research facilities at TriposDiscovery Research Centre, allowing the company to reduce itsdependency on outsourcing. We then concluded the year by announcing anagreement to acquire Optive Research Inc. The Optive transactionsecured access to several important products for Tripos, and we gainedvaluable complementary staff resources, expertise and industryrelationships."
Tripos achieved the following results for the 12 months endingDec. 31, 2004:

--
For 2004, Tripos posted revenues of $64.8 million, a 20 percent increase from the previous year´s revenues of $54.1 million.

--
Income from operations was $2.4 million in 2004, compared with a loss from operations of $5.4 million in 2003, a positive swing of $7.8 million.

--
Pretax income was $2.2 million for the year, compared with $3.7 million for the same period in 2003. In contrast, fiscal year 2003 included a pretax gain of $6.7 million on the sale of shares of Arena Pharmaceuticals Inc.

--
Net income for 2004 was $232,000, or $0.02 per diluted share after including a valuation allowance for certain deferred tax assets. This compares with a net income of $2.1 million or $0.23 per diluted share for the full year 2003. Net income for 2003 also included the after-tax gain of $3.8 million related to the sale of Arena shares. As in prior periods, Tripos was required to maintain a valuation allowance against deferred tax assets created by current and previous net operating losses in certain tax jurisdictions. Thus, the effective income tax rate was higher and net income lower than would have been the case if the company could recognize these tax benefits. The establishment of the valuation allowance for the deferred tax assets does not impair the company´s ability to use the deferred tax assets upon achieving profitability in those tax jurisdictions.

Tripos achieved the following results for the three months endingDec. 31, 2004:

-- Revenues for the fourth quarter of 2004 were $17.3 million,
compared with $12.6 million in the fourth quarter of 2003, an
increase of 37 percent.

-- Operating income for the fourth quarter was $856,000, compared
with an operating loss of $2.5 million in 2003.

-- Pretax income for the fourth quarter of 2004 was $1.5 million,
compared with a pretax loss of $800,000 in the previous year.

-- After including a valuation allowance for certain deferred tax
assets, net income for the fourth quarter of 2004 was
$246,000, or $0.03 per basic and diluted share, compared with
a net loss of $452,000, or $0.05 per basic share, in the
fourth quarter of 2003.

"Our business performed well in 2004," Dr. McAlister said."Revenue from discovery research products and services increased by 37percent from $26.2 million in 2003 to $36 million in 2004. Discoveryinformatics products and support exhibited steady growth of 4 percentfrom $23.7 million in 2003 to $24.6 million in 2004. Discoveryinformatics services also increased 24 percent from $3.2 million in2003 to $4 million in 2004."

2004 Operational Highlights

Tripos made progress during the year on several strategic fronts:

Strengthened and expanded business relationships

-- Renegotiated its multiyear Pfizer Inc. file enrichment
contract. It now represents up to $90 million in revenues over
its four-year term and covers work on the next stage of the
collaboration: hit follow-up and large library production.

-- Expanded its discovery informatics contract with Schering AG.
It now covers final development and deployment of the initial
phase of the Enterprise Chemical Information Management System
and provides Tripos with increased incremental funding.

-- Announced a multimillion-dollar, multiyear extension of its
global software license agreement with Pfizer

-- Commenced a new license agreement with Bayer HealthCare AG.
Tripos began deploying SYBYL and UNITY globally across Bayer´s
drug discovery and development organization.

-- Established drug discovery partnerships with Strida Pharma
Inc., Chronogen Inc., Divergence Inc., Sanofi-Synthelabo
Recherche, the European Molecular Biology Laboratory and the
German Cancer Research Center. Through these relationships,
Tripos is helping to discover new compounds to treat cancer,
cardiovascular disorders, parasitic infestations and other
diseases.

-- Signed more discovery research contracts than in any previous
year since beginning this business operation in 1998

Introduced new products

-- Launched LITHIUM(TM) 2.0, a collaborative decision-support
environment that enables biologists and medicinal chemists to
view, interact with and share complex 3-D molecular data,
providing them with access to vital research information

-- Released SARNavigator(TM) 1.5, a new research application that
allows scientists to rapidly and objectively analyze the large
quantities of chemical and biological data resulting from real
or virtual high-throughput screening

-- Introduced SYBYL(R) 7.0. This new version of the company´s
molecular modeling environment for drug discovery research is
available on multiple platforms, including the Linux operating
system upgrade, Red Hat Enterprise Linux 3.0.

Announced strategic acquisition

-- Agreed to acquire Optive Research, a molecular discovery
software company. The deal was announced on Dec. 22, 2004, and
subsequently closed on Jan. 5, 2005. Through this transaction,
Tripos gained access to 15 software products developed by
Optive Research, which are complementary to its existing
product lines, including Concord(R), a leading program for
creating three-dimensional molecular models, EA_Inventor for
de novo molecular design and Optive´s Microsoft Windows-based
Benchware(TM) applications to facilitate the expansion of its
products to the desktop.

2005 Outlook

"We are looking forward to 2005 as we go to market with newdesktop software products and seek new discovery research partnershipsfor our Lead Discovery Program. Each of these activities is expectedto have a positive impact on our performance," Dr. McAlister said. "Wewill continue to focus on delivering operating profits for ourshareholders, while making the strategic investments in both discoveryinformatics and discovery research."

Webcast Information

Tripos will host a conference call and webcast today at 10 a.m.EST to discuss these financial results in detail. Those who want toparticipate in the webcast should visit the Tripos Web site athttp://www.tripos.com. The Tripos webcast archive will be availablebeginning at 1 p.m. EST today, and will remain on the Tripos Web sitethrough March 22, 2005.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology andinnovative science to deliver consistently superior chemistry-researchproducts and services for the biotechnology, pharmaceutical and otherlife science industries. Tripos collaborates with clients toaccelerate and improve the creation of life-enhancing products. WithinTripos´ Discovery Informatics (DI) business, the company providessoftware products and consulting services to develop, manage, analyzeand share critical drug discovery information. Within Tripos´Discovery Research (DR) business, Tripos´ medicinal chemists andresearch scientists partner directly with clients in their researchinitiatives, leveraging state-of-the-art information technologies andresearch facilities. Headquartered in St. Louis, Mo., Tripos spans theworld with global research operations and an international clientbase. Further information on Tripos can be found athttp://www.tripos.com.

This press release may contain certain statements that areforward-looking and involve risks and uncertainties. Words such as"expects," "anticipates," "projects," "estimates," "intends," "plans,""believes," variations of such words and similar expressions areintended to identify such forward-looking statements. These statementsare based on current expectations and projections made by managementand are not guarantees of future performance. Therefore, actualevents, outcomes and results may differ materially from what isexpressed or forecast in such forward-looking statements. We haveidentified certain factors that could cause actual results to differmaterially from the forward-looking statements in our Annual Report onForm 10-K, our Quarterly Reports on Form 10-Q, and our Current Reportson Form 8-K. Except as otherwise required under federal securitieslaws and the rules and regulations of the SEC, we do not have anyintention or obligation to update or revise any forward-lookingstatements, whether as a result of new information, future events,changes in assumptions or otherwise.
Tripos and the Tripos logo are registered trademarks of Tripos,Inc., and/or its affiliates in the United States and certain othercountries. All other trademarks mentioned in this document are theproperty of their respective owners.


Tripos, Inc. Condensed Results of Operations (in thousands, except per-share data) Three Months Twelve Months Ended Ended -------------- ---------------- 31-Dec 31-Dec 31-Dec 31-Dec 04 03 04 03 Net sales Discovery informatics products and support $6,414 $6,091 $24,639 $23,702 Discovery informatics services 1,324 207 4,005 3,241 Discovery research products and services 9,545 6,140 36,004 26,245 Hardware 33 179 131 960 -------------- ---------------- Total net sales 17,316 12,617 64,779 54,148 Cost of sales 9,317 7,472 32,752 26,240 -------------- ---------------- Gross profit 7,999 5,145 32,027 27,908 Operating expenses Sales and marketing 3,096 3,294 12,560 13,195 Research and development 1,861 2,717 9,294 12,917 General and administrative 2,186 1,595 7,771 7,241 -------------- ---------------- Total operating expenses 7,143 7,606 29,625 33,353 Income (loss) from operations 856 (2,461) 2,402 (5,445) Other income (loss), net 665 1,669 (160) 9,114 -------------- ---------------- Income (loss) before income taxes 1,521 (792) 2,242 3,669 Income tax expense (benefit) 1,275 (340) 2,010 1,569 -------------- ---------------- Net income (loss) $246 $(452) $232 $2,100 ============== ================ Basic income (loss) per share $0.03 $(0.05) $0.03 $0.23 Diluted income (loss) per share $0.03 $(0.05) $0.02 $0.23 Basic weighted average shares 9,310 8,992 9,206 8,949 Diluted shares outstanding 9,396 8,992 9,357 9,333 Tripos, Inc. Consolidated Balance Sheets (in thousands) 31-Dec 31-Dec 04 03Assets:Current assets: Cash and cash equivalents $4,171 $2,945 Marketable securities 341 1,121 Accounts receivable 15,666 16,662 Inventory 12,007 12,863 Deferred income taxes 188 -- Prepaid expenses 5,603 5,054 ---------------- Total current assets 37,976 38,645Property and equipment, less accumulated depreciation 30,672 27,926Capitalized development costs, net 2,159 2,417Goodwill 965 965Investments recorded at cost 1,397 1,352Deferred income taxes -- --Other, net 112 390 ---------------- Total assets $73,281 $71,695 ================Liabilities and shareholders´ equity:Current liabilities: Current portion of long-term debt and capital leases $4,506 $10,510 Accounts payable 1,796 2,405 Accrued expenses 9,076 7,688 Deferred revenue 21,945 17,079 Deferred income taxes 25 219 ---------------- Total current liabilities 37,348 37,901Long-term portion of capital leases 2,653 2,463Long-term debt 3,697 3,915Deferred income taxes 1,717 422Shareholders´ equity Common stock 94 90 Additional paid-in capital 37,394 36,457 Retained earnings (deficit) (8,089) (8,321) Other comprehensive income (deficit) (1,533) (1,232) ---------------- Total shareholders´ equity 27,866 26,994 Total liabilities and shareholders´ equity $73,281 $71,695 ================

--30--KS/se* CONTACT: Tripos, Inc. Jim Rubin, Chief Financial Officer 314-647-8837 OR (Media only) Waggener Edstrom Bioscience Lisa Osborne, Account Director 425-638-7134 [e-mail] KEYWORD: MISSOURI INDUSTRY KEYWORD: MEDICAL DEVICES PHARMACEUTICAL MEDICALBIOTECHNOLOGY SOFTWARE EARNINGS CONFERENCE CALLS SOURCE: Tripos, Inc.Copyright Business Wire 2005

(c) 2005 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.

Autor: © Business Wire , 12:02 22.02.05

[Kautzie]

http://www.nano-invests.de/